In this study, we employed two osteosarcoma cell lines, HOS and HOS-143B, to understand the mechanism of how daraxonrasib affects osteosarcoma with KRAS WT versus the oncogenic mutation KRAS G12S [17]. Here, KRAS is linked to osteosarcoma.